Table 2.
Major Bleeding Outcomes at 12 Months Stratified by Non‐High (<25) or High (≥25) PRECISE‐DAPT Score and Receiver Operating Characteristic Analyses Assessing the Performance of the Score
| Kaplan‐Meier event rate, n/total n (%) | HR (95% CI) | P value | C‐statistic (95% CI) | P value | ||
|---|---|---|---|---|---|---|
| Non‐high PRECISE‐DAPT score (<25) | High PRECISE‐DAPT score (≥25) | |||||
| All patients, n=66 295 | 891/52 401 (1.8) | 526/13 894 (3.9) | 2.2 (2.0–2.5) | <0.001 | 0.64 (0.63–0.66) | <0.001 |
| Age ≥75 y, n=17 454 | 207/7150 (3.0) | 383/10 304 (3.8) | 1.3 (1.1–1.5) | 0.003 | 0.57 (0.55–0.60) | <0.001 |
| Body weight <60 kg, n=3299 | 62/1921 (3.3) | 55/1378 (4.1) | 1.2 (0.9–1.8) | 0.236 | 0.56 (0.51–0.61) | 0.033 |
| Women, n=18 513 | 217/12 397 (1.8) | 198/6116 (3.3) | 1.9 (1.5–2.3) | <0.001 | 0.62 (0.60–0.65) | <0.001 |
| Anemia, n=9847* | 143/4579 (3.2) | 270/5268 (5.3) | 1.7 (1.4–2.0) | <0.001 | 0.60 (0.58–0.63) | <0.001 |
| Kidney dysfunction, n=10 599 † | 55/2354 (2.4) | 290/8245 (3.6) | 1.5 (1.1–2.0) | 0.005 | 0.61 (0.58–0.64) | <0.001 |
| Cancer within 3 y, n=1330 | 29/694 (4.3) | 42/636 (6.8) | 1.6 (1.0–2.6) | 0.050 | 0.59 (0.53–0.66) | 0.009 |
Results are shown for the whole study population of patients with myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy as well as for subgroups. PRECISE‐DAPT indicates Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy. HR indicates hazard ratio.
*
Anemia is hemoglobin <120 g/L for women and <130 g/L for men.
†
Kidney dysfunction is creatinine clearance <60 mL/min per 1.73 m2.